Laboratory Co. of America (NYSE:LH) Stock Acquired Rep. Robert Bresnahan, Jr.

Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently bought shares of Laboratory Co. of America Holdings NYSE: LH. In a filing disclosed on May 31st, the Representative disclosed that they had bought between $1,001 and $15,000 in Laboratory Co. of America stock on May 15th. The trade occurred in the Representative's "JP MORGAN BROKERAGE ACCOUNT" account.

Representative Robert Bresnahan, Jr. also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Zimmer Biomet NYSE: ZBH on 5/15/2025.
• Sold $15,001 - $50,000 in shares of Elevance Health NYSE: ELV on 5/15/2025.
• Sold $15,001 - $50,000 in shares of PepsiCo NASDAQ: PEP on 5/15/2025.
• Sold $1,001 - $15,000 in shares of WEC Energy Group NYSE: WEC on 5/15/2025.
• Purchased $15,001 - $50,000 in shares of Advanced Micro Devices NASDAQ: AMD on 5/15/2025.
• Purchased $1,001 - $15,000 in shares of Hershey NYSE: HSY on 5/15/2025.
• Purchased $1,001 - $15,000 in shares of Kraft Heinz NASDAQ: KHC on 5/15/2025.
• Sold $1,001 - $15,000 in shares of Exxon Mobil NYSE: XOM on 5/15/2025.
• Sold $1,001 - $15,000 in shares of Danaher NYSE: DHR on 5/15/2025.
• Sold $1,001 - $15,000 in shares of International Flavors & Fragrances NYSE: IFF on 5/15/2025.

Laboratory Co. of America Stock Performance

Shares of Laboratory Co. of America stock traded up $1.77 during trading on Friday, reaching $253.92. The company's stock had a trading volume of 442,869 shares, compared to its average volume of 636,661. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.30 and a current ratio of 1.44. The business's fifty day moving average price is $236.87 and its 200-day moving average price is $238.69. The firm has a market cap of $21.25 billion, a price-to-earnings ratio of 28.79, a price-to-earnings-growth ratio of 1.71 and a beta of 0.81. Laboratory Co. of America Holdings has a one year low of $192.38 and a one year high of $258.59.

Laboratory Co. of America (NYSE:LH - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The medical research company reported $3.84 EPS for the quarter, topping analysts' consensus estimates of $3.73 by $0.11. The business had revenue of $3.35 billion for the quarter, compared to analyst estimates of $3.41 billion. Laboratory Co. of America had a return on equity of 15.29% and a net margin of 5.73%. The firm's revenue for the quarter was up 5.3% on a year-over-year basis. During the same period in the previous year, the company posted $3.68 earnings per share. As a group, equities research analysts predict that Laboratory Co. of America Holdings will post 16.01 earnings per share for the current year.

Laboratory Co. of America Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 11th. Stockholders of record on Thursday, May 29th will be paid a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.13%. Laboratory Co. of America's payout ratio is presently 33.29%.

Institutional Investors Weigh In On Laboratory Co. of America

Large investors have recently modified their holdings of the stock. Golden State Wealth Management LLC grew its stake in shares of Laboratory Co. of America by 88.1% in the 1st quarter. Golden State Wealth Management LLC now owns 111 shares of the medical research company's stock valued at $26,000 after purchasing an additional 52 shares during the period. Graney & King LLC bought a new stake in shares of Laboratory Co. of America in the 4th quarter valued at approximately $26,000. North Capital Inc. bought a new stake in shares of Laboratory Co. of America in the 1st quarter valued at approximately $27,000. TruNorth Capital Management LLC bought a new stake in shares of Laboratory Co. of America in the 1st quarter valued at approximately $28,000. Finally, Larson Financial Group LLC grew its position in Laboratory Co. of America by 140.4% during the 1st quarter. Larson Financial Group LLC now owns 125 shares of the medical research company's stock worth $29,000 after acquiring an additional 73 shares during the last quarter. 95.94% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, CAO Peter J. Wilkinson sold 829 shares of the stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $242.26, for a total transaction of $200,833.54. Following the sale, the chief accounting officer now directly owns 2,054 shares in the company, valued at $497,602.04. This represents a 28.75% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Adam H. Schechter sold 6,105 shares of the stock in a transaction that occurred on Monday, May 12th. The stock was sold at an average price of $248.73, for a total value of $1,518,496.65. Following the sale, the chief executive officer now owns 98,962 shares in the company, valued at approximately $24,614,818.26. This trade represents a 5.81% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 11,592 shares of company stock worth $2,841,820 in the last three months. Insiders own 0.84% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on LH shares. Piper Sandler restated a "neutral" rating and set a $280.00 price target (up from $260.00) on shares of Laboratory Co. of America in a research note on Tuesday, May 6th. Barclays boosted their price target on Laboratory Co. of America from $240.00 to $250.00 and gave the company an "equal weight" rating in a research note on Wednesday, April 30th. Robert W. Baird boosted their price target on Laboratory Co. of America from $253.00 to $267.00 and gave the company an "outperform" rating in a research note on Wednesday, April 30th. Truist Financial boosted their price target on Laboratory Co. of America from $274.00 to $290.00 and gave the company a "buy" rating in a research note on Monday, May 12th. Finally, Citigroup upgraded Laboratory Co. of America from a "neutral" rating to a "buy" rating and boosted their price target for the company from $250.00 to $300.00 in a research note on Tuesday, March 4th. Four investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Laboratory Co. of America has a consensus rating of "Moderate Buy" and a consensus target price of $272.92.

About Representative Bresnahan

Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania's 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania's 8th Congressional District. He declared candidacy for the 2026 election. Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.

About Laboratory Co. of America

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.